ArticleAmerican journal of clinical and experimental urology2025
Ectonucleotidases and purinergic receptors in mouse prostate gland.
Article in American journal of clinical and experimental urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesExtracellular ATP/ADP and its metabolite adenosine play crucial roles in cellular signaling by interacting with P2 and P1/adenosine receptors. These signaling molecules are regulated by ectonucleotidases, which convert ATP/ADP into adenosine. While recent studies suggest impaired ATP hydrolysis in the aging prostate, the expression and function of ectonucleotidases and purinergic receptors in the prostate gland remain unclear. This study aims to characterize the expression patterns of purinergic enzymes and receptors in the mouse prostate and investigate their functional implications.
methodsMouse prostate glands were isolated and analyzed using immunofluorescent staining and microscopy imaging with specific antibodies to detect purinergic enzymes and receptors. Functional studies were conducted to assess prostate smooth muscle contraction in response to purinergic agonists, particularly α,β-meATP and ATPγS.
resultsOur analysis revealed distinct expression patterns of purinergic enzymes and receptors in the prostate: Ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1) and P2X1 receptors were predominantly localized in prostate smooth muscle cells, ENTPD2 and ecto-5'-nucleotidase (NT5E) in prostate interstitial cells, and alkaline phosphatase (ALPL) in prostate epithelial cells. Notably, ENTPD1 was identified as a key ectonucleotidase expressed in mouse prostate smooth muscle cells. Functionally, P2X1-mediated smooth muscle contraction was triggered by α,β-meATP. However, ATPγS induced contraction even after P2X1 desensitization, suggesting the involvement of additional P2Y receptors. Further analysis confirmed the presence of P2Y1, P2Y2, and P2Y11 receptors in mouse prostate smooth muscle, likely mediating the ATPγS-induced contraction.
conclusionsThis study provides a comprehensive characterization of purinergic signaling components in the mouse prostate. The identification of ENTPD1 in smooth muscle cells and the functional role of multiple P2Y receptors in smooth muscle contraction highlight potential regulatory mechanisms of prostate function. These findings lay the groundwork for future research on purinergic signaling in prostate physiology and its potential implications in age-related dysfunction, both in rodents and humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.